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Electroconvulsive therapyAbstract Background and aim of study: Electroconvulsive therapy (ECT) is one of the safest
methods used for the treatment of patients with mental illness today. It is associated with surge
in heart rate and blood pressure for a brief period of time. However, as an extreme complication,
the hemodynamic response to ECT can produce myocardial ischaemia and even infarction, as well
as transient neurological ischaemic deﬁcits, intracerebral haemorrhages, and cortical blindness. This
study is aimed towards ﬁnding a reliable drug that can prevent this untoward hemodynamic
response in immediate post-ECT period.
Place and duration of study: The study was conducted at Combined Military Hospital Skardu after
permission from the hospital ethics committee from January 2011 to December 2011.
Study design: One thirty-four American society of Anaesthesiology (ASA) I & II patients of both
genders were divided randomly in three groups named A, B and C. Patients were induced short gen-
eral anaesthesia as per set protocol. Group A patients were given no additional drug, while group B
patients had lignocaine 1 mg/kg and group C patients nitroglycerine (NTG) 3 l/kg respectively just
after induction. Heart rate (HR) and mean arterial pressure (MAP) were recorded 2 min after
induction of anaesthesia just prior to ECT shock and then 1 min after ECT administration.
28 M.U. Zahoor et al.Operation deﬁnitions: Signiﬁcant rise in heart rate was deﬁned as an increase in heart rate of 10 or
more beats per minute after administration of ECT shock from baseline.
Signiﬁcant rise in MAP was deﬁned as the rise in MAP of 15 mm of Hg or more from the baseline
after administration of ECT shock.
Results: Thirty-three (75%) of 44 patients in group A showed signiﬁcant rise in HR as compared to
group B where no patient showed a signiﬁcant increase in HR (p< .05). In terms of MAP 29 (65%)
out of 44 patients showed a signiﬁcant rise in group A and 22 (52%) out of 42 patients in group B
showed similar results showing statically insigniﬁcant difference between the groups. When compar-
ing patients of groups A and C, only 11 (22%) out of 48 patients showed signiﬁcant rise in HR and
13 (27%) patients showed signiﬁcant rise in MAP. The difference was statistically signiﬁcant in both
variables (p< .05).
Conclusion: NTG provided more hemodynamic stability in post-ECT period as compared to ligno-
caine which only prevented a surge in HR without any effect on MAP. We conclude that NTG can
safely be instituted for anaesthesia in ECT patients for prevention of hemodynamic stress response.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.1. Introduction
Electroconvulsive Therapy (ECT) is one of the most effective
therapy for the treatment of depressive episode severe, some
cases of acute and chronic schizophrenia and bipolar affective
disorder. Historically ECT was performed without anaesthe-
sia, but currently it is performed under general anaesthesia
with muscle relaxation. The aim of this brief general anaesthe-
sia is to avoid the untoward effects of ECT without interfering
with advantageous effects of ECT [1,2].
ECT is not free from its own hazards. Intense muscle
contractions after ECT can lead to tongue bite, laryngospasm,
bone fractures and joint dislocations. Autonomic nervous
system stimulation causes bradycardia followed by tachycardia
and hypertension. This can lead to cardiac arrest from brad-
yarrhythmias on the one hand and stroke and myocardial
infarction in high risk patients due to tachycardia and hyper-
tension. The hemodynamic response to ECT can produce
myocardial ischaemia and even infarction, as well as transient
neurological ischaemic deﬁcits, intracerebral haemorrhages,
and cortical blindness. In patients with severe cardiovascular
disease, reduced intracranial compliance and vascular pathol-
ogy, it may precipitate haemorrhage.
The aim of this study was to ﬁnd an effective pharmacolog-
ical agent to avoid acute tachycardia and hypertension in post-
ECT period. Number of drugs can be used to prevent this
untoward hemodynamic response, but we chose two conve-
niently available drugs in most operation theatre settings i.e.
Nitroglycerin and Lignocaine.
Nitroglycerin (NTG) is a potent vasodilator traditionally
used to treat angina attacks. It has a short half-life of 1–
4 min. In the body, mitochondrial aldehyde dehydrogenase
converts NTG into nitric oxide. NO increase the cGMP levels
in the smooth muscles through which in turn reduces the free
calcium concentration in the smooth muscle cell. The action is
more pronounced on the veins causing blood pooling in this
vessel compartment and thus prevents and treats hypertension
[3]. The dose required is approximately 3 lg/kg.
Lignocaine is relatively short acting drug with elimination
half-life of 90–120 min. It alters signal conduction in neurones
by blocking voltage gated sodium channels in the neurone cell
membrane that are responsible for signal propagation. With
sufﬁcient blockage the membrane of the postsynaptic neuronewill not depolarise and will thus fail to transmit an action
potential, thus blunting the sympathetic response [4]. The rec-
ommended dose for this purpose is 1–1.5 mg/kg.
2. Materials and methods
This study was conducted in the department of Anaesthesiolo-
gy and department of Mental Health, Combined Military Hos-
pital Skardu between January 2011 and December 2011. The
study design was randomised controlled trial and was con-
ducted after approval from hospital ethical committee. The
hospital ethics committee stated that they have gone through
the synopsis of the study and are permitting the department
of anaesthesia and mental health to proceed with the study
as it can beneﬁt the patients undergoing ECT. The help of
institution’s biostatistician was acquired for the assessment
of the appropriate sample size who used Altman’s nomogram
for the calculation of sample size. On this basis, 134 American
Society of Anesthesiologist (ASA) physical status I & II pa-
tients were selected from those receiving general anaesthesia
for ECT, and were divided into three groups. Groups were
allocated using table randomisation. An independent observer
was assigned to generate random allocation sequence. Patients
with history of asthma, hypertension, heart blocks, recent MI/
CVA (less than 6 weeks old), and severe osteoporosis were ex-
cluded from the study.
Patients allocated to groups A, B and C were 44, 42 and 48
respectively. The patients were randomly divided into three
groups A, B and C. All were made NPO a per anaesthesia pro-
tocols. In operating room 18G cannula was passed and pa-
tients were given injection ondansetron 4 mg slow
intravenous as an antiemetic. Induction was carried out with
2 mg/kg propofol and 1 mg/kg succinylcholine. Anaesthesia
was maintained with 100% oxygen with facemask. In patients
of group A no additional drug was given, in group B patients
injection lignocaine 1 mg/kg was given and injection NTG
3 lg/kg was administered to patients of group C. HR and
MAP were recorded 2 min after administration of anaesthesia
just prior to ECT shock and 1 min after delivery of ECT
shock.
An SR2 biphasic brief-pulse ECT machine was used to de-
liver the electrical stimulus via electrodes placed at patient
forehead. Controlled or assisted ventilation was continued
Table 2 Comparison of Pre-ECT and 1 min post-ECT heart





Group A (n= 44) 82.5 ± 14.4 91 ± 9.1
Group B (n= 42) 87.2 ± 11.8 83.5 ± 8.7
Group C (n= 48) 83.8 ± 10.6 88.6 ± 9.7






Group A (n= 44) 89.3 ± 16 112.8 ± 18.7
Group B (n= 42) 96.8 ± 16.6 113.9 ± 14.5
Group C (n= 48) 95.6 ± 16.3 106.5 ± 16.2
Table 4 Comparison of patients having signiﬁcant rise in
heart rate 1 min after ECT in three groups.
Group Signiﬁcant (Per cent) Insigniﬁcant (Per cent)
A (n= 44) 33 11
B (n= 42) 0 42
C (n= 48) 11 37
Table 5 Comparison of patients having signiﬁcant rise in
MAP 1 min after ECT in three groups.
Group Signiﬁcant Insigniﬁcant
A (n= 44) 29 15
B (n= 42) 22 20
C (n= 48) 13 35
Use of lignocaine or nitroglycerine for blunting of hemodynamic stress response 29with 100% oxygen until adequate spontaneous ventilation
returned.
All statistical analysis was performed using SPSS version 20
and chi square test was used to determine the relation among
interventions. A p value of < 0.05 was considered statistically
signiﬁcant.
2.1. Operation deﬁnitions
Signiﬁcant rise in heart rate was deﬁned as an increase in heart
rate of 10 or more beats per minute after administration of
ECT shock from baseline.
Signiﬁcant rise in MAP was deﬁned as the rise in MAP of
15 mm of Hg or more from the baseline after administration
of ECT shock.
3. Results
The demographic data of patients in each group are shown in
Table 1. Data showing pre- and post-ECT heart rate and mean
arterial pressure in three groups is shown in the Tables 2 and 3
respectively.
Out of 44 patients in group A, 33 (75%) patients showed
signiﬁcant rise in heart rate, as compared to group B in which
no signiﬁcant rise in 1 min post-ECT heart rate was recorded.
The p value was found to be less than 0.001 which was statis-
tically signiﬁcant. 29 (65%) patients of Group A showed sig-
niﬁcant rise in 1 min post-ECT MAP as compared to 22
(52%) patients of Group B (p= 0.087).
When comparing groups A and C, only 11 (22%) patients
out of 48 in group C showed signiﬁcant rise in 1 min post-
ECT HR and 13 patients (27%) showed signiﬁcant rise in
1 min post-ECT MAP. The difference was signiﬁcant
p< 0.001 in both cases showing better hemodynamic stability
with NTG. The data are summarised in Tables 4 and 5.
Keeping aforesaid in view, it is inferred that NTG provided
more hemodynamic stability in post-ECT period as compared
to Lignocaine and no drug.
4. Discussion
Electroconvulsive Therapy (ECT) provokes a generalised sei-
zure. This was ﬁrst described in 1938 and was performed with-
out anaesthesia for almost 30 years [5]. In recent years, ECT
has presumed an increasingly signiﬁcant role in the treatment
for severe and medication resistant depression and mania, as
well as in the treatment of schizophrenic patients with suicidal
risk and catatonic symptoms [6]. Typically the acute phase of
ECT is performed three times a week for 6–12 treatments. In
successful cases, initial clinical improvement is usually evident
after three to ﬁve treatments. Maintenance therapy can beTable 1 Demographic data of patients in each group.
Group Age (Years) Sex
Male (n) Female (n)
A (n= 44) 38 ± 10 19 25
B (n= 42) 34 ± 13 19 23
C (n= 48) 37 ± 9 23 25performed at progressively increasing intervals from once a
week to once a month to prevent relapses [7].
Understanding neurohormonal related physiological re-
sponse of ECT is pivotal in providing anaesthesia to patients
undergoing this procedure so that its beneﬁcial effects can be
spared while counteracting its adverse effects. Most modern
ECT devices deliver a brief-pulse current, which is thought
to cause fewer cognitive effects than the sine-wave currents
which were originally used in ECT. Central nervous system
seizure activity rather than electrical stimulus is responsible
for the beneﬁcial effect of ECT but the exact mechanism of
the therapeutic effects is not yet understood. When an electric
current is applied to brain via transcutaneous electrodes, the
resultant electroencephalographic spike (EEG) and wave
activity are accompanied by a generalised motor seizure
and an acute cardiovascular response, which results in
marked increase in cerebral blood ﬂow and intracranial pres-
sure [8]. However the magnitude of the acute hyperdynamic
response to ECT appears to be independent of the duration
of motor and EEG activity [9]. The hemodynamic response
to ECT can produce myocardial ischaemia and even infarc-
tion [10], as well as transient neurological ischaemic deﬁcits,
30 M.U. Zahoor et al.intracerebral haemorrhages, and cortical blindness. Short
term memory loss is common after ECT and more serious
cognitive dysfunction have been described in the ECT litera-
ture, even though there is no scientiﬁc evidence of direct neu-
rological evidence [11].
Hyperdynamic cardiovascular response that occurs after
ECT is result of central activation of the autonomic nervous
system. A brief parasympathetic discharge occurs immediately
for the ﬁrst 10–15 s after application of electrical current with a
sympathetic discharge following within seconds. Within 10–12
s of the sympathetic surge caused by epinephrine and norepi-
nephrine release, sinus tachycardia and arterial hypertension
may develop. Plasma epinephrine increases to 15 times normal
level, and plasma norepinephrine peaks can become three
times higher than under normal resting conditions, with peak
levels occurring within 60 s of electrical stimulation [12,13].
Systolic blood pressure is transiently increased by 30–40%
and heart rate is increased by 20% or more, resulting in a
two- to fourfold increase in the rate-pressure product, an index
of myocardial consumption. Studies have shown that the con-
centration of epinephrine decreases towards normal values
5 min after ECT, and norepinephrine levels remain increased
for twice as long. These hemodynamic changes produce an
abrupt increase in myocardial oxygen consumption. It may
be beneﬁcial to administer drugs which blunt the hemody-
namic stress response. There has always been a nagging
thought in anaesthetist’s mind to control this hemodynamic
surge.
The purpose of our study was to blunt the hemodynamic
insult associated with ECT to prevent the cardiovascular
complications using a pharmacological agent. We used an
adequate depth of general anaesthesia with brief muscle
paralysis as our anaesthesia technique in the control group
and then adding lignocaine and NTG in two different
groups to ﬁnd out whether these drugs provide an additional
beneﬁt on preventing hemodynamic surge associated with
neurohormonal response of ECT. There are number of stud-
ies in which pharmacological management is instituted to-
wards prevention of sympathetic surge in patients receiving
ECT. However not much studies have speciﬁcally targeted
the two drugs used in our research. In a study conducted
at San Diego by Weigner MB et al. they concluded that
lignocaine was not effective enough in attenuating the stress
response associated with the ECT current [12]. Another
study conducted by O Flaherty D et al. demonstrated that
NTG produced better hemodynamic instability than esmolol
[13].
Our study showed that lignocaine was effective enough
to control the surge in HR but was unable to attenuate
the rise in MAP in post-ECT period as compared to con-
trol group. On the other hand NTG was effective enough
in controlling rise in both HR and MAP in immediate
post-ECT period. We conclude that 3ug/kg NTG is supe-
rior to 1 mg/kg lignocaine in preventing hemodynamic
surge in patients receiving ECT and practice can be insti-
tuted on regular basis in patients undergoing ECT
procedure.5. Limitations
This study is conducted at skardu which is a high altitude and
can cause hemodynamic changes itself. The size of sample is
small and results cannot be generalised on population.
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